Literature DB >> 1313923

A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating.

J M Tatem1, C Weeks-Levy, A Georgiu, S J DiMichele, E J Gorgacz, V R Racaniello, F R Cano, S J Mento.   

Abstract

The attenuated phenotype of Sabin 3 poliovirus compared with its neurovirulent progenitor strain has been largely accounted for by mutations in the genome at positions 472 and 2034 (G. D. Westrop, K. A. Wareham, D. M. A. Evans, G. Dunn, P. D. Minor, D. I. Magrath, F. Taffs, S. Marsden, M. A. Skinner, G. C. Schild, and J. W. Almond, J. Virol. 63:1338-1344, 1989). By sequencing vaccine virus RNA, we recently identified another Sabin 3-specific mutation at position 2493 (U----C), which predicts an Ile----Thr change at the sixth residue of VP1 (C. Weeks-Levy, J. M. Tatem, S. J. DiMichele, W. Waterfield, A. F. Georgiu, and S. J. Mento, Virology 185:934-937, 1991). Viruses generated by using cDNAs which represent the vaccine sequence (LED3) and a derivative (VR318) possessing a single base change to the wild-type nucleotide (U) at 2493 were used to determine the impact of the 2493 mutation on virus phenotype. The VP1 proteins of LED3 and VR318 viruses were distinguishable by denaturing electrophoretic analysis. LED3 produced smaller plaques in Vero cells than VR318 virus did. Neurovirulence testing of these cDNA-derived viruses in monkeys demonstrated that the 2493 mutation in LED3 virus is attenuating.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313923      PMCID: PMC241086     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

Review 1.  RNA virus evolution and the control of viral disease.

Authors:  E Domingo
Journal:  Prog Drug Res       Date:  1989

2.  Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus.

Authors:  C Weeks-Levy; J M Tatem; S J DiMichele; W Waterfield; A F Georgiu; S J Mento
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

3.  Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees.

Authors:  J M Tatem; C Weeks-Levy; S J Mento; S J DiMichele; A Georgiu; W F Waterfield; B Sheip; C Costalas; T Davies; M B Ritchey
Journal:  J Med Virol       Date:  1991-10       Impact factor: 2.327

4.  Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.

Authors:  K M Chumakov; L B Powers; K E Noonan; I B Roninson; I S Levenbook
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

5.  Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA.

Authors:  K Kirkegaard
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

Authors:  G D Westrop; K A Wareham; D M Evans; G Dunn; P D Minor; D I Magrath; F Taffs; S Marsden; M A Skinner; G C Schild
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

7.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

8.  Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase.

Authors:  S van der Werf; J Bradley; E Wimmer; F W Studier; J J Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Characterization of Vero cells.

Authors:  S K Swanson; S J Mento; C Weeks-Levy; B D Brock; K J Kowal; R E Wallace; M B Ritchey; F R Cano
Journal:  J Biol Stand       Date:  1988-10

10.  Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources.

Authors:  G Dunn; N T Begg; N Cammack; P D Minor
Journal:  J Med Virol       Date:  1990-10       Impact factor: 2.327

View more
  24 in total

1.  Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus.

Authors:  T Kanno; D Mackay; T Inoue; G Wilsden; M Yamakawa; R Yamazoe; S Yamaguchi; J Shirai; P Kitching; Y Murakami
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

3.  Differential recruitment of B and T cells in coxsackievirus B4-induced pancreatitis is influenced by a capsid protein.

Authors:  A I Ramsingh; W T Lee; D N Collins; L E Armstrong
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine.

Authors:  Evaggelos Dedepsidis; Ioannis Karakasiliotis; Eleni Paximadi; Zaharoula Kyriakopoulou; Dimitrios Komiotis; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

5.  Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina.

Authors:  Judith E Mueller; Maël Bessaud; Q Sue Huang; Laura C Martinez; Patricia A Barril; Viviane Morel; Jean Balanant; Judy Bocacao; Joanne Hewitt; Brad D Gessner; Francis Delpeyroux; Silvia V Nates
Journal:  Appl Environ Microbiol       Date:  2009-01-05       Impact factor: 4.792

6.  Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.

Authors:  S S Whitehead; K Juhasz; C Y Firestone; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Environmental surveillance of poliovirus in sewage water around the introduction period for inactivated polio vaccine in Japan.

Authors:  Tomofumi Nakamura; Mitsuhiro Hamasaki; Hideaki Yoshitomi; Tetsuya Ishibashi; Chiharu Yoshiyama; Eriko Maeda; Nobuyuki Sera; Hiromu Yoshida
Journal:  Appl Environ Microbiol       Date:  2015-01-02       Impact factor: 4.792

9.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

10.  A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.

Authors:  M Dan; J K Chantler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.